174 related articles for article (PubMed ID: 7936652)
21. Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor-I receptor.
Surmacz E; Sell C; Swantek J; Kato H; Roberts CT; LeRoith D; Baserga R
Exp Cell Res; 1995 May; 218(1):370-80. PubMed ID: 7737373
[TBL] [Abstract][Full Text] [Related]
22. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function.
Kuo ML; Chou YW; Chau YP; Huang TS
Mol Carcinog; 1997 Apr; 18(4):221-31. PubMed ID: 9142217
[TBL] [Abstract][Full Text] [Related]
23. The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways.
Hernandez-Muñoz I; Malumbres M; Leonardi P; Pellicer A
Oncogene; 2000 May; 19(23):2745-57. PubMed ID: 10851075
[TBL] [Abstract][Full Text] [Related]
24. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
Palmby TR; Abe K; Karnoub AE; Der CJ
Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
[TBL] [Abstract][Full Text] [Related]
25. R-Ras C-terminal sequences are sufficient to confer R-Ras specificity to H-Ras.
Hansen M; Rusyn EV; Hughes PE; Ginsberg MH; Cox AD; Willumsen BM
Oncogene; 2002 Jun; 21(28):4448-61. PubMed ID: 12080475
[TBL] [Abstract][Full Text] [Related]
26. Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
Tokumitsu Y; Nakano S; Ueno H; Niho Y
J Cell Physiol; 2000 May; 183(2):221-7. PubMed ID: 10737897
[TBL] [Abstract][Full Text] [Related]
27. RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases.
Aguirre-Ghiso JA; Frankel P; Farias EF; Lu Z; Jiang H; Olsen A; Feig LA; de Kier Joffe EB; Foster DA
Oncogene; 1999 Aug; 18(33):4718-25. PubMed ID: 10467419
[TBL] [Abstract][Full Text] [Related]
28. Guanine nucleotide exchange factors: activators of Ras superfamily proteins.
Overbeck AF; Brtva TR; Cox AD; Graham SM; Huff SY; Khosravi-Far R; Quilliam LA; Solski PA; Der CJ
Mol Reprod Dev; 1995 Dec; 42(4):468-76. PubMed ID: 8607978
[TBL] [Abstract][Full Text] [Related]
29. RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts.
Ladeda V; Frankel P; Feig LA; Foster DA; Bal de Kier Joffe E; Aguirre-Ghiso JA
Biochem Biophys Res Commun; 2001 May; 283(4):854-61. PubMed ID: 11350063
[TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of R-ras3: a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution.
Kimmelman A; Tolkacheva T; Lorenzi MV; Osada M; Chan AM
Oncogene; 1997 Nov; 15(22):2675-85. PubMed ID: 9400994
[TBL] [Abstract][Full Text] [Related]
31. Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway.
Perletti GP; Concari P; Brusaferri S; Marras E; Piccinini F; Tashjian AH
Oncogene; 1998 Jun; 16(25):3345-8. PubMed ID: 9681835
[TBL] [Abstract][Full Text] [Related]
32. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant.
Rapp UR; Troppmair J; Beck T; Birrer MJ
Oncogene; 1994 Dec; 9(12):3493-8. PubMed ID: 7970709
[TBL] [Abstract][Full Text] [Related]
33. Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav.
Crespo P; Bustelo XR; Aaronson DS; Coso OA; Lopez-Barahona M; Barbacid M; Gutkind JS
Oncogene; 1996 Aug; 13(3):455-60. PubMed ID: 8760286
[TBL] [Abstract][Full Text] [Related]
34. Resistance of NIH3T3 cells to v-fes transformation induced by a dominant negative H-ras mutant.
Ogiso Y; Yokoyama T; Watari H; Shih TY; Kuzumaki N
Exp Cell Res; 1993 Oct; 208(2):415-21. PubMed ID: 7690710
[TBL] [Abstract][Full Text] [Related]
35. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
Yokoyama T
Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
[TBL] [Abstract][Full Text] [Related]
36. Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells.
Li W; Michieli P; Alimandi M; Lorenzi MV; Wu Y; Wang LH; Heidaran MA; Pierce JH
Oncogene; 1996 Aug; 13(4):731-7. PubMed ID: 8761294
[TBL] [Abstract][Full Text] [Related]
37. Critical role of Rho in cell transformation by oncogenic Ras.
Prendergast GC; Khosravi-Far R; Solski PA; Kurzawa H; Lebowitz PF; Der CJ
Oncogene; 1995 Jun; 10(12):2289-96. PubMed ID: 7784077
[TBL] [Abstract][Full Text] [Related]
38. Malignant transformation of a preneoplastic hamster epidermal cell line by the EJ c-Ha-ras-oncogene.
Storer RD; Stein RB; Sina JF; DeLuca JG; Allen HL; Bradley MO
Cancer Res; 1986 Mar; 46(3):1458-64. PubMed ID: 3510726
[TBL] [Abstract][Full Text] [Related]
39. Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation.
Graham SM; Cox AD; Drivas G; Rush MG; D'Eustachio P; Der CJ
Mol Cell Biol; 1994 Jun; 14(6):4108-15. PubMed ID: 8196649
[TBL] [Abstract][Full Text] [Related]
40. trans-Dominant suppressor mutations of the H-ras oncogene.
Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
